News in other languages: NEOVACS

30/06	Neovacs renforce son portefeuille stratégique de propriété intellectuelle
30/06	Neovacs : Neovacs renforce son portefeuille stratégique de propriété intellectuelle avec le dépôt d’une demande de brevet couvrant une nouvelle famille de lipides dédiés à la délivrance d’ARN
29/06	Neovacs : Cotation des actions Néovacs regroupées
15/06	Financements dilutifs et fonds vautours : le législateur s'en mêle enfin
22/05	Bourse : Richemont brille, Estée Lauder renonce à Puig, Kioxia grossit

More news

Managers and Directors: NEOVACS

Manager	Title	Age	Since
Hugo Brugière CEO	Chief Executive Officer	-	-
Alexandre Courtoux DFI	Director of Finance/CFO	-	01/10/2020
Laurent Reber CTO	Chief Tech/Sci/R&D Officer	56	-

Director	Title	Age	Since
Jean-Jacques Bertrand CHM	Chairman	87	28/05/2003
Baudouin Hallo BRD	Director/Board Member	-	01/05/2020
Hugo Brugière CHM	Chairman	-	-

More insiders

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NEOVACS	-1.00%	-1.00%	-	-	182K
LONZA GROUP AG	-1.29%	-3.11%	-0.39%	+4.92%	49.7B
REVOLUTION MEDICINES, INC.	+3.25%	-1.15%	+373.07%	+594.23%	38.09B
BEONE MEDICINES AG	-1.37%	+4.37%	+7.37%	+57.52%	35.29B
IQVIA HOLDINGS INC.	-1.94%	-0.73%	+26.39%	-6.79%	35.13B
CELLTRION, INC.	+0.06%	+1.56%	+4.41%	+27.42%	27.22B
ASCENDIS PHARMA A/S	+2.05%	-1.66%	-	-	16.14B
MEDPACE HOLDINGS, INC.	-0.24%	-0.69%	+67.47%	+116.09%	15.36B
EUROFINS SCIENTIFIC SE	+1.12%	+1.91%	+15.90%	+19.65%	13.89B
ICON PUBLIC LIMITED COMPANY	+0.13%	+1.15%	+15.50%	-30.77%	13.02B
Average	+0.03%	-0.57%	+63.71%	+97.78%	27.09B
Weighted average by Cap.	-0.14%	-0.64%	+74.47%	+118.90%

See all sector performances

NEOVACS is a major player in the therapeutic vaccines for the treatment of autoimmune and / or inflammatory diseases. Its proprietary products are vaccine candidates developed from its own technology platform for Kinoid products used in lupus disease and allergies. This innovative approach allows the patient's immune system to regulate the damage caused by overproduction of cytokines (active immunotherapy) such as IL-4/IL-13/IgE. The company also uses the skills of its experienced team to invest in companies developing innovative products (BioTech) and medical devices (MedTech).

Employees

Sector

Biotechnology & Medical Research

More about the company

Income Statement and Estimates

More financial data

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

30/06	Neovacs bolsters its strategic intellectual property portfolio
11/02	Neovacs S.A. announced that it has received ?0.25 million in funding from Hanover Square Investments Pte Limted	CI

Market Cap	4.09K 4.68K 3.77K 3.48K 6.56K 451K 6.7K 45.1K 17.74K 221K 17.57K 17.19K 760K	P/E 2023 *	-	P/E 2024	-
Enterprise Value	-201K -230K -185K -171K -322K -22.15M -329K -2.22M -872K -10.85M -864K -845K -37.34M	EV / Sales 2023	-	EV / Sales 2024	-
Free-Float	99%	Yield 2023 *	-	Yield 2024	-

30/06	Neovacs bolsters its strategic intellectual property portfolio
11/02	Neovacs S.A. announced that it has received ?0.25 million in funding from Hanover Square Investments Pte Limted	CI
21/11	Neovacs S.A. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
21/10/25	Neovacs S.A. announced that it expects to receive ?0.25 million in funding	CI
12/08/25	Neovacs S.A. announced that it has received ?0.25 million in funding from European High Growth Opportunities Manco S.A.	CI
30/04/25	Neovacs S.A. Auditor Raises 'Going Concern' Doubt	CI
30/04/25	Neovacs S.A. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
17/03/25	Neovacs S.A. announced a financing transaction	CI
04/02/25	Neovacs: consideration of delisting, share price surges
04/11/24	Neovacs S.A. Reports Earnings Results for the Half Year Ended June 30, 2024	CI
02/11/24	Tech's Tangled Path with Microsoft
17/06/24	Neovacs: collaboration agreement with CNRS
10/06/24	Neovacs: presents results from vaccine candidates

	2023	2024
Net sales	533K 610K 492K 454K 855K 58.78M 874K 5.88M 2.31M 28.79M 2.29M 2.24M 99.1M	434K 497K 400K 369K 696K 47.82M 711K 4.79M 1.88M 23.42M 1.86M 1.82M 80.62M
Net income	-8.74M -10.01M -8.07M -7.44M -14.02M -964M -14.33M -96.44M -37.93M -472M -37.57M -36.75M -1.62B	-32.91M -37.66M -30.37M -28M -52.77M -3.63B -53.94M -363M -143M -1.78B -141M -138M -6.12B
Net Debt	-237K -271K -218K -201K -379K -26.06M -388K -2.61M -1.03M -12.76M -1.02M -994K -43.94M	-205K -235K -189K -174K -329K -22.6M -336K -2.26M -890K -11.07M -881K -862K -38.1M

NEOVACS Stock Euronext Paris

Stocks

ALNEV

FR001400HDX0

Biotechnology & Medical Research

Valuation: NEOVACS

Latest news : NEOVACS

News in other languages: NEOVACS

Quotes and Performance

Managers and Directors: NEOVACS

Other Biotechnology & Medical Research

Financials

Company Profile

Income Statement and Estimates

End-of-day quote Euronext Paris Other stock markets 05/02/2024			5-day change	1st Jan Change
1.980 ^EUR	-1.00%		-1.00%	-1.00%